Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Apellis Pharmaceuticals (APLS) Leases (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Leases data on record, last reported at $18.2 million in Q4 2025.

  • For Q4 2025, Leases rose 13.13% year-over-year to $18.2 million; the TTM value through Dec 2025 reached $18.2 million, up 13.13%, while the annual FY2025 figure was $18.2 million, 13.13% up from the prior year.
  • Leases reached $18.2 million in Q4 2025 per APLS's latest filing, down from $19.7 million in the prior quarter.
  • Across five years, Leases topped out at $22.5 million in Q1 2021 and bottomed at $14.6 million in Q2 2025.
  • Average Leases over 5 years is $18.2 million, with a median of $18.0 million recorded in 2023.
  • Peak YoY movement for Leases: surged 69.3% in 2021, then decreased 20.68% in 2023.
  • A 5-year view of Leases shows it stood at $19.9 million in 2021, then decreased by 5.8% to $18.7 million in 2022, then fell by 10.68% to $16.7 million in 2023, then fell by 3.95% to $16.1 million in 2024, then increased by 13.13% to $18.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $18.2 million in Q4 2025, $19.7 million in Q3 2025, and $14.6 million in Q2 2025.